NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, degenerative and auto-immune indications, announced today that it will present favorable results of pre-clinical studies of its proprietary PLacental eXpanded (PLX) cells for additional clinical indications on October 18th, at the “3rd World Congress on Regenerative Medicine” in Leipzig, Germany.
